Finance

Lists
EVT:ETR
Evotec SE
€ 3.21
-1.89%
(-0.062) 1D
9-р сарын 4, 17:35:17 (GMT+2)  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for EVT...
Open
€ 3.27
High
€ 3.27
Low
€ 3.19
Mkt. cap
561.77 сая
Avg. vol.
774.92 мян
Volume
1.09 сая
52-wk high
€ 7.30
52-wk low
€ 3.12
EPS
-€ 1.11
Shares outstanding
177.91 сая
No. of employees
4 мян
Open
€ 3.27
High
€ 3.27
Low
€ 3.19
Mkt. cap
561.77 сая
Avg. vol.
774.92 мян
Volume
1.09 сая
52-wk high
€ 7.30
52-wk low
€ 3.12
EPS
-€ 1.11
Shares outstanding
177.91 сая
No. of employees
4 мян
News stories
From web sources and news partners
Profile
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
About Evotec SE
CEO-
Employees4.46 мян
Founded1993
Headquarters-
SectorHealth care
Websiteevotec.com
Last report
2026 оны 7-р сарын 14
Fiscal period
Q2 2026
EPS / Est. (EUR)
- / -
Revenue / Est. (EUR)
143.48 сая / 143.50 сая
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
163.89 сая
253.27 сая
156.64 сая
143.48 сая
Cost of goods sold
163.95 сая
174.81 сая
158.21 сая
145.06 сая
Cost of revenue
163.95 сая
174.81 сая
158.21 сая
145.06 сая
Research and development expenses
8.71 сая
9.83 сая
10.08 сая
10.26 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
42.31 сая
44.35 сая
43.79 сая
39.29 сая
Operating expense
43.53 сая
55.25 сая
44.85 сая
87.74 сая
Total operating expenses
207.48 сая
230.06 сая
203.07 сая
232.80 сая
Operating income
-43.59 сая
23.21 сая
-46.42 сая
-89.32 сая
Other non operating income
1.19 сая
-33.96 сая
1.89 сая
-839.00 мян
EBT including unusual items
-42.96 сая
29.46 сая
-122.18 сая
-48.12 сая
EBT excluding unusual items
-43.36 сая
18.35 сая
-47.40 сая
-94.00 сая
Income tax expense
127.00 мян
14.84 сая
-244.00 мян
-1.47 сая
Effective tax rate
-0.30%
50.37%
0.20%
3.06%
Other operating expenses
-7.50 сая
1.07 сая
-9.02 сая
38.20 сая
Net income
-43.09 сая
14.62 сая
-121.94 сая
-46.65 сая
Net profit margin
-26.29%
5.77%
-77.84%
-32.51%
Earnings per share
-0.24
-
-
-
Interest and investment income
841.00 мян
11.84 сая
-
-
Interest expense
-2.28 сая
-
-2.58 сая
-2.97 сая
Net interest expenses
-1.44 сая
11.84 сая
-2.58 сая
-2.97 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.27 сая
41.91 сая
-22.60 сая
-64.88 сая
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google аппс